Horizons Marijuana Life Sciences Index ETF

With the exception of Aphria, Tilray, Canopy Growth, and Aurora Cannabis were trading at a premium to the peer median EV-to-EBITDA multiple.

Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.

The Horizons Marijuana Life Sciences ETF (HMMJ) had fallen by about 1.2% as of noon on March 20, while the ETFMG Alternative Harvest ETF (MJ) had declined by nearly 0.8%.

Markets rebounded today after the recent sell-off fueled by US-China trade tensions.

On February 18, Canopy Growth (WEED) received a price target upgrade from Canaccord Genuity.

In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.

The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.

Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.

Cormark Securities raised its target price for Canopy Growth to 40 Canadian dollars from 33 Canadian dollars, which represents an increase of almost 21%.

On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.

CIBC downgraded HEXO to “neutral” from “outperform” and reduced the target price to 8.5 Canadian dollars from 9.5 Canadian dollars.

This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.

Cannabis legalization is a vital topic in the US. Meanwhile, vaping related deaths continue to rise. Will vaping concerns kill the US cannabis dream?

AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.

Aurora Cannabis should report its fourth-quarter earnings results on Thursday. So far, September has been positive. As of Monday, the stock has gained 8.7%.

Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.

Many people expected the Cannabis 2.0 products, including cannabis edibles, to hit the markets by mid-December 2019. However, the products got delayed.

Marijuana is an old but growing market in California. Notably, California became the first state to legalize medical marijuana in 1996.

After Tilray’s second-quarter earnings, Benchmark reduced its target price to $80 from $120. Cowen and Company reduced the target price to $60 from $150.

On May 28, Bill C-45, Canada’s recreational cannabis legalization bill, saw further progress in the Senate.

Canopy Growth (WEED) (CGC) has continued to deepen its roots in the United States with a recent announcement that could be a game changer.

MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.

Last week, the overall cannabis sector remained subdued. Sector ETFs, such as the Horizons Marijuana Life Sciences ETF (HMMJ), closed about 8.15% lower.

Federally, cannabis legalization saw daylight in Canada in 2018. The Cannabis Act legalized recreational marijuana in October 2018. Now, the country is all set for the second wave of legalization, Cannabis 2.0, which includes cannabis edibles, cannabis-infused beverages, extracts, and various other products. Let’s dig into this more. Canada’s second wave of legalization Next month, […]

Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.

After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.

Cannabis 2.0 legalization will take place in Canada next month. Cannabis players are gearing up to expand in the edibles market.

The reason cannabis stocks are rising could be because October 17 is approaching.

On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.

On January 18, Canopy Growth was trading at an EV-to-EBITDA multiple of 110.9x.

Today, cannabis stocks are trading in the green despite the weakness in the broader market. The ETFMG Alternative Harvest ETF was up 2.5% as of 2:00 PM ET.

Canopy Growth reported its earnings for the first quarter of 2019 on August 14. The company is one of the largest cannabis producers by capacity.

It looks like cannabis stocks had a great day. Innovative Industrial Properties (IIPR), Cronos Group (CRON), and Tilray (TLRY) are all surging today.

On December 9, Canopy Growth (CGC) appointed David Klein as its new CEO effective January 14. He’s the current CFO of Constellation Brands.

Amid a subdued cannabis sector, Aurora Cannabis (ACB) stock has taken a serious hit and is down 36.4% this month. Is this the right time to invest?

During 3Q18, Canopy Growth increased its inventory and biological assets to a value of 108.3 Canadian dollars from 56 million Canadian dollars in 3Q17.

While Aphria’s consensus target price fell after its earnings, most analysts remain bullish on the stock. The overall “strong-buy” rating didn’t change.

Aurora Cannabis reported its fourth-quarter results on Wednesday after the market closed. Did the company impress investors?

Canopy Growth is preparing for the US market, but Tilray (TLRY) is not far behind.

Marijuana products are top-rated among Americans. Illinois will see recreational marijuana products for sale on January 1.

Cannabis stocks had a difficult 2019. Besides cannabis companies losing out on revenue and profitability, many external factors also affected the sector. While pessimism drove the industry this year, a Raymond James analyst predicts things can turn around in 2020. Let’s take a look. Raymond James feels the cannabis sector could rebound On December 16, […]

This morning turned brutal for the overall market with the S&P 500 Index sinking as much as 2.34% through the first half of the day on the back of the trade dispute between the United States and China.

On September 18, cannabis stock Tilray (TLRY) popped about 27% to an all-time high of $153.8 in the mid-day session.

Aurora Cannabis stock got a boost at the beginning of the month. The company updated its guidance for the fourth quarter.

Cannabis ETFs traded on a largely negative note last week.

Aurora Cannabis (ACB) is going through a rough patch. This year, the company’s stock has lost 60.9% of its value as of December 23.

The FDA has issued warning letters to 15 companies involved in illegal sales of non-psychoactive CBD products. What’s the legal market’s potential?

The week ending February 16 wasn’t so positive for marijuana stocks even though the broader market indexes ended in the positive territory.

Cannabis players are having a hard time this year. Regulatory concerns and weaker earnings due to the vaping-related crisis took a toll on the sector.

With more countries now warming up to cannabis, let’s look at how Mexico is shaping up in terms of cannabis legalization.